Open an account

Chemours

CC · NYSE

$12.97+$0.35 (+2.77%)TodayMarket closed ·
Prev close $12.62

About CC

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The company is headquartered in Wilmington, Delaware and currently employs 5,700 full-time employees. The company went IPO on 2015-06-19. The Company’s segments include Titanium Technologies, Thermal & Specialized Solutions and Advanced Performance Materials. The Titanium Technologies segment is a provider of titanium dioxide pigment, a premium white pigment used to deliver whiteness, brightness, opacity and protection in various applications. The Thermal & Specialized Solutions segment is a provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a provider of high-end polymers and advanced materials. Its flagship products include brands such as Opteon, Freon, Ti-Pure, Nafion, Teflon, Viton, and Krytox. The firm serves over 2,700 customers in approximately 110 countries.

Employees
5,700
Headquarters
Wilmington, Delaware
Listed
Jun 19, 2015
Sector
Materials
Industry
Chemicals
Website
chemours.com

CC key statistics

Market cap
1.95B
Price-earnings ratio
0.00
Dividend yield
2.76%
Average volume
2.09M
Volume
2.98M
Open price
$12.56
High today
$13.06
Low today
$12.52
52 Week high
$28.67
52 Week low
$10.44

Chemours (CC) at a glance

As of Oct 20, 2026, Chemours (CC) shares are priced at $12.97, giving the company a market cap of 1.95B, a price-to-earnings ratio of 0.00 and a dividend yield of 2.76%.

Today the stock has traded between $12.52 and $13.06. The current price is 3.6% above the day's low and 0.7% below its high.

Volume so far is 2.98M shares, above the average of 2.09M shares a day.

Over the past year Chemours has ranged from $10.44 to $28.67, and now sits 14% of the way up that range.

Chemours met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.42 per share against an estimate of $0.4317.

The average analyst price target is $19.31, 48.8% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 9 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 14 analystsAvg $19.31
Low
$17.17
Now
$12.97
High
$25.20

CC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 87.3% on average.

  1. Q3 FY24: reported $0.40 per share against an estimate of $0.2924
  2. Q4 FY24: reported $0.11 per share against an estimate of $0.1198
  3. Q1 FY25: reported $0.13 per share against an estimate of $0.2191
  4. Q2 FY25: reported $0.58 per share against an estimate of $0.4705
  5. Q3 FY25: reported $0.20 per share against an estimate of $0.2612
  6. Q4 FY25: reported $0.05 per share against an estimate of $0.0705
  7. Q1 FY26: reported $0.05 per share against an estimate of -$0.0491
  8. Q2 FY26: reported $0.42 per share against an estimate of $0.4317

CC news

  • Press releaseGlobe Newswire

    NYSE: CC: Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages CC Investors with Losses to Contact the Firm

  • Press releasePRNewswire

    INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Chemours Company to Contact Law Firm

  • Press releasePRNewswire

    What Does The Chemours Company's 18.63% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

  • Press releaseGlobe Newswire

    SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of December 7, 2026 in The Chemours Company Lawsuit - CC

  • Press releasePRNewswire

    Shareholders who lost money in shares of The Chemours Company (NYSE: CC) should contact Wolf Haldenstein Immediately

  • Press releasePRNewswire

    Investor Alert: Chemours (CC) has been Sued for Securities Fraud Over Alleged Misstatements made to Investors

  • Press releasePRNewswire

    What Should The Chemours Company Investors Know After 18.63% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

  • Press releasePRNewswire

    CC Investors Have Opportunity to Lead The Chemours Company Securities Fraud Lawsuit with SBS Law

Similar companies

Companies in the same industry as Chemours

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.